Insulin Potentiation Therapy (IPT)

The original trendsetter was Insulin Potentiated Therapy (IPT), also known as Insulin Potentiated Low-dose Therapy (IPTLD). This chemotherapy approach was first proposed in 1933 by Dr. Perez Garsia and was first successfully used to treat cancer in 1943.

Since the original work by Dr. Perez Garcia, IPTLD has spread across the entire world. There is approaching almost 100 years of clinical use of IPTLD by physicians worldwide to treat cancer!

Over time, this treatment sustainability approaches eternity in the universe of historical medical therapies.

It is essential always to remember that the word physician in Hebrew, Rāphè, can be translated to mean healer. We physicians, doctors, and medical providers are not cutters, not providers of prescription medications or injections, but are healers. We should embrace this origin more to heart.

Insulin potentiated low-dose therapy follows a more holistic, integrative approach to cancer treatment. The word holistic points to a different way of thinking—a different paradigm. A holistic treatment perspective can apply a more conventional medical treatment in a safer, more thoughtful, and integrative approach.

The goal here is to work with, preserve, and heal the whole rather than work against, damage, and destroy the whole or part. The last one hundred years of cancer treatment have followed the paradigm of destruction en route to the path to healing. It is time for a different approach.

The perfect example of this holistic, safer, smarter, and more integrative approach is Insulin Potentiated Low-Dose Therapy (IPTLD). Insulin potentiated therapy recognizes that a 2 x 4 piece of lumber upside the head with maximum to tolerated chemotherapy doesn’t heal; it only damages and destroys.

Maximum to tolerated chemotherapy can damage cancer cells. Still, research points to a significant increase in the metastatic spread of cancer due to the maximum tolerated chemotherapy and the widespread collateral damage to the healthy cells of the body.

Why is this important?

Over ninety percent of morbidity and mortality associated with cancer results from the metastatic spread of cancer. Beyond the metastatic spread, the immune system is the apparent target of collateral damage resulting from the maximum tolerated chemotherapy approach that has dominated conventional medicine for seventy years.

Instead, taking a significantly lower dose and directing it with insulin still targets cancer yet preserves and even promotes the immune system. More, the lower dose approach broadens the anti-cancer effects through angiogenesis targeting.

As a result, this holistic approach to a more conventional medical therapy works more with the body to preserve and heal the whole body, not just target the tumor while destroying the body in the process. That is the benefit of a holistic, integrative approach to cancer treatment at Brio-Medical.